CAMBRIDGE, Mass.--(BUSINESS WIRE)--Javelin Pharmaceuticals, Inc. (Amex: JAV - News) today announced today that it intends to offer to sell, subject to market and other conditions, approximately 7,100,000 shares of its common stock in an underwritten public offering. The Company intends to grant the underwriters a 30-day option to purchase up to approximately an additional 1,065,000 shares of its common stock to cover over-allotments. All of the shares are being offered by the Company.
